Form 4: Elevance Health CEO Gail Boudreaux Sells Shares Under 10b5-1 Trading Plan

Elevance Health's CEO, Gail Boudreaux, executed multiple sales of common stock on July 22, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 22, 2024, Gail Boudreaux, the President and CEO of Elevance Health, Inc., sold shares of common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on April 19, 2024.
• A total of 33,950 shares were sold at prices ranging from $498.50 to $504.27.
• The transactions resulted in Ms. Boudreaux directly owning 126,709 shares of Elevance Health common stock, and indirectly owning 60 shares through a spouse's revocable trust.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating insider transactions. The sentiment is neutral as it simply reports facts about stock sales under a pre-arranged plan.

Industry Context

Executive stock sales are a common occurrence, and sales under 10b5-1 plans are generally viewed as less impactful since they are pre-scheduled. Investors often monitor insider transactions for signals about a company's prospects, but pre-planned sales are less informative.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
• The impact is likely to be minimal due to the pre-planned nature of the sales.

Key Dates